Drugs / VBI-S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06072430 | Aug 2024 → Dec 2025 overdue | infectious disease with sepsis | Vivacelle Bio | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-02-29 | Vivacelle Bio | Results Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients vivacellebio.com ↗
The results were astonishing, with VBI-S proving 100% effective in elevating mean blood pressure by 10 mmHg or more. |
| 2023-02-10 | Vivacelle Bio | Results Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients vivacellebio.com ↗
All 20 patients enrolled in the trial met the primary endpoint of elevating mean arterial blood pressure by at least 10 mmHg within an average of 1.5 hours. |
| 2022-10-20 | Vivacelle Bio | Results (BPRW) Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis vivacellebio.com ↗
Each of the thirteen(13) patients treated so far in the trial met the primary goal which was an elevation of mean arterial blood pressure by at least 10 mmHg. |
| 2020-04-29 | Vivacelle Bio | Results Black Doctor Says He Has Developed Clinical Treatment For COVID-19 Patients That Increases Oxygen Levels vivacellebio.com ↗
However, while intravenous infusion of the treatment has demonstrated encouraging preliminary results in a phase IIa clinical study, Dr. Simpkin’s invention is still currently an experimental drug. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VBI-S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06072430 ↗ |
| Modality | Other / unclassified | “VBI-S is made of small particles of specific lipids called micelles and liposomes” NCT06072430 ↗ |